After senolysis, CD38i→precursor residual ΔNAD ≠ precursor→CD38i residual
STATUS_LABEL: NEGATIVE
polarity: negative swarm_id: L12 card_sha256: 1ed0a3f5647f29a7529258922f7de4036027d96166c1a197b2baf3f4e6fc7689 risk_class: research-discussion note: PASS_NEGATIVE — shipped as discussion (not claim/hypothesis). Soft-complete order∩CD38i∩precursor∩senolytic empty / non-match; matched order H2H residual ΔNAD after senolysis remains UNKNOWN. L5–L11 ranking/dual/stack surplus ≠ temporal order proof.
Claim
After documented senescent-cell / SASP clearance, residual tissue ΔNAD from a matched CD38-inhibitor-then-NAD-precursor sequence differs from residual tissue ΔNAD from the reverse precursor-then-CD38-inhibitor sequence at matched total exposure — pre-registered residual_CD38i_then_precursor outside an equivalence band of residual_precursor_then_CD38i (order-asymmetry H2H after matched senolytic/SASP run-in).
Why it matters
Longevity stacks often treat CD38i and NAD precursors as order-irrelevant once senescent load falls, or infer protocol order from which lever “wins” in ranking cards. Distinct from L5/L6 (which lever wins ≠ temporal order), L9 (stack surplus ≠ order), L10 (precursor absolute/fractional dual), L11 (CD38i absolute vs fractional dual). Soft-claims: discussion — soft-complete order∩CD38i∩precursor∩senolytic empty / non-match; matched order H2H remains UNKNOWN. L5–L11 are not proof of order asymmetry; co-treatment ≠ order; 78c monotherapy ≠ order readout.
Mechanism sketch
Subtract-before-add: clear SASP-driven CD38+ macrophage load first, then run two sequential arms (CD38i→precursor vs precursor→CD38i) at matched total exposure and score residual tissue ΔNAD. CD38 gates age NAD decline and NMN fate; SASP induces CD38-high macrophages that drain tissue NAD; senescent/SASP ablation lowers CD38 and partially restores NAD via an NMN-dependent ecto-block route; 78c-class CD38i improves aged-mouse healthspan as monotherapy (not an order panel). Incomplete clearance / residual CD38+ load can interact with which lever hits first — that interaction is predicted, not measured. Concurrent CD38i+NR co-treatment is not a sequential order H2H.
Prior art
- PMID 27304511 / DOI 10.1016/j.cmet.2016.05.006 / PMC4911708 — age NAD↓ requires CD38; CD38 gates NMN fate in vivo (Camacho-Pereira 2016) — CD38–NAD / NMN-gating prior for residual assays.
- PMID 33199924 / DOI 10.1038/s42255-020-00305-3 / PMC7908681 — SASP induces CD38-high macrophages that reduce tissue NAD (Covarrubias 2020) — subtract-before-add / incomplete-clearance motivation; not order panel.
- PMID 33199925 / DOI 10.1038/s42255-020-00298-z / PMC8752031 — senescent/SASP ablation ↓CD38 and partially restores NAD; ecto-CD38 block raises NAD via NMN-dependent process (Chini 2020) — post-clearance baseline prior, not CD38i↔precursor order H2H.
- PMID 35263032 / DOI 10.1111/acel.13589 / PMC9009115 — CD38i 78c increases lifespan/healthspan in chronological aging (Tarragó 2022) — monotherapy tool prior, not order panel after senolysis.
Baseline claimed
After senolysis, CD38i→precursor residual tissue ΔNAD ≠ precursor→CD38i residual at matched total exposure — or L5–L11 ranking / dual / stack cards already settle temporal order of CD38i vs precursor after clearance.
Baseline measured
CD38 gates age NAD / NMN fate LITERATURE (PMID 27304511). SASP→CD38+ macrophages→tissue NAD↓ LITERATURE (PMID 33199924). Clearance ↓CD38 + partial NAD rebound; ecto-block NMN-dependent LITERATURE (PMID 33199925). 78c aged-mouse benefit LITERATURE monotherapy (PMID 35263032). Matched H2H CD38i→precursor vs precursor→CD38i residual ΔNAD after senolysis UNKNOWN (soft-complete order∩CD38i∩precursor∩senolytic = 0; adjacent co-treatment PMID 33871064 / review 36678315 / clearance prior / token false-positives ≠ order H2H). Order asymmetry PREDICTION. L5–L11 do not already prove this — ranking ≠ order; duals ≠ order; stack surplus ≠ order; co-treatment ≠ order.
Actionable limitations
- Do not treat L5–L11 as proving L12 — ranking / stack surplus / absolute-vs-fractional duals never ran matched CD38i→precursor vs precursor→CD38i residual ΔNAD after clearance; soft-complete empty ≠ demonstrated order asymmetry.
- Co-treatment ≠ order — concurrent CD38i + NR (e.g. PMID 33871064) or synergistic-stack reviews do not report sequential residual arms after matched senolytic/SASP run-in.
- Incomplete clearance / target-load can interact with order; Chini clearance/ecto-block and 78c monotherapy are not order panels; L9 stack surplus ≠ temporal-order H2H; no dosing.
Method
propose-assay
Prediction variables
| name | kind | assay | threshold |
|---|---|---|---|
| CD38_gates_age_NAD_and_NMN | LITERATURE | Aging NAD metabolome vs CD38; NMN fate (Camacho-Pereira 2016) | age NAD↓ requires CD38; gates NMN fate (PMID 27304511) |
| SASP_CD38_macrophage_NAD_drain | LITERATURE | Senescent/SASP-conditioned macrophage CD38 and tissue NAD (Covarrubias 2020) | SASP induces CD38-high macrophages that reduce tissue NAD (PMID 33199924) |
| clearance_CD38_drop_NAD_rebound_ecto_NMN_dependent | LITERATURE | Senescent/SASP ablation → CD38↓ + partial NAD↑; ecto-CD38 block NAD boost (Chini 2020) | CD38↓ with partial NAD recovery; ecto-block raises NAD via NMN-dependent route (PMID 33199925) — clearance prior, not order panel |
| CD38i_78c_aged_mouse_monotherapy | LITERATURE | Chronological-aging 78c survival/healthspan (Tarragó 2022) | lifespan/healthspan class effect as monotherapy — not CD38i↔precursor order panel after senolysis (PMID 35263032) |
| matched_order_H2H_residual_panel | UNKNOWN | Matched senolytic/SASP run-in → arm A CD38i then NAD-precursor vs arm B precursor then CD38i at matched total exposure; residual tissue ΔNAD ± CD38 activity | dedicated order H2H residual panel not found (soft-complete order∩CD38i∩precursor∩senolytic = 0; adjacent co-treatment/review/clearance non-matches) — UNKNOWN |
| order_asymmetry_residual_deltaNAD | PREDICTION | Pre-registered aged tissue or SASP-conditioned system; verified clearance → CD38i→precursor vs precursor→CD38i at matched total exposure; residual ΔNAD readout | residual_CD38i_then_precursor outside pre-registered equivalence band of residual_precursor_then_CD38i (α/N pre-specified) — do not invent observed Δ or dosing |
| competing_order_equivalence_or_incomplete_clearance | PREDICTION | Same design; falsifier if residuals fall inside the equivalence band when clearance is verified — or if apparent asymmetry is only incomplete-clearance / exposure-mismatch / assay-definition artifact | order-equivalence / incomplete-clearance / exposure-mismatch / assay-definition failure allowed as pre-registered competing outcomes |
Ablate
- remove matched H2H CD38i→precursor vs precursor→CD38i residual ΔNAD arms after documented senolysis / SASP clearance at matched total exposure: Without the sequential order H2H residual readout, solo-lever LITERATURE and co-treatment cannot show order asymmetry of residual ΔNAD.
- remove documented clearance run-in with CD38↓ / partial NAD rebound verification before both sequential arms: Without subtract-first confirmation, the card collapses into co-treatment or order-without-clearance and loses the post-senolysis subtract-before-add frame.
- remove L5–L11≠proof + co-treatment≠order + soft-complete-empty≠asymmetry + 78c-monotherapy≠order discipline: Treating L5–L11 ranking/duals/stack, concurrent CD38i+NR, or empty PubMed as already deciding order asymmetry would invent an H2H result left UNKNOWN.
Refute if
On the pre-registered order H2H residual panel after verified clearance, residual_CD38i_then_precursor falls inside the equivalence band of residual_precursor_then_CD38i (order equivalence), when CD38↓ is verified — especially under incomplete clearance, exposure mismatch, or when apparent asymmetry is only an assay-definition artifact under the pre-registered residual definitions.
Ask a human
Lock tissue (WAT/liver), clearance verification (CD38 activity + SC/SASP marker), matched total exposure for CD38i (78c-class) and NAD precursor (NMN/NR-class) sequential arms, and residual ΔNAD definition before claiming order asymmetry after senolysis; do not treat L5–L11 as proof; co-treatment ≠ order; no dosing.
Cheap IP
kill_cost_tier=2 · time_to_refute=6w · ip_class=subtract-before-add · vault_hold=no
Execution
execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=L5–L11 (ranking/duals/stack surplus ≠ CD38i↔precursor order H2H residual proof)